Cerebral is a clinical-stage pharmaceutical company developing innovative treatments for uncontrolled neurological diseases.
Cerebral is dedicated to improving the lives of patients living with severe refractory epilepsy and other uncontrolled neurological diseases.
Cerebral was founded in 2019 by Kyle Robertson and Ho Anh. The company is headquartered in San Francisco, California.
Cerebral Therapeutics uses a proprietary implanted infusion system to deliver continuous doses of CT-010 intracerebroventricularly (ICV). This novel drug-device combination treatment is intended to increase brain exposure thereby maximizing efficacy, reducing systemic drug exposure, and improving safety while enhancing therapy adherence.
Cerebral Therapeutics' intracerebroventricular (ICV) infusion therapy may offer a more efficacious and reliable approach to treating neurological diseases for which oral medications are not able to achieve adequate control and/or are limited by systemic toxicities.
Cerebral has raised $35M in a Series B funding round on Jan 07, 2020. Backers included RA Capital Management, Perceptive Advisors, Vivo Capital, LLC and Granite Point Capital Management, L.P.